G

Genovis AB
STO:GENO

Watchlist Manager
Genovis AB
STO:GENO
Watchlist
Price: 28.05 SEK 3.13% Market Closed
Market Cap: 1.8B SEK
Have any thoughts about
Genovis AB?
Write Note

Genovis AB
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genovis AB
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
G
Genovis AB
STO:GENO
Cash from Operating Activities
kr37.3m
CAGR 3-Years
73%
CAGR 5-Years
60%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Cash from Operating Activities
kr773m
CAGR 3-Years
-7%
CAGR 5-Years
34%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Cash from Operating Activities
kr178.4m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Cash from Operating Activities
kr406m
CAGR 3-Years
6%
CAGR 5-Years
17%
CAGR 10-Years
19%
MedCap AB (publ)
STO:MCAP
Cash from Operating Activities
kr308.3m
CAGR 3-Years
41%
CAGR 5-Years
29%
CAGR 10-Years
28%
M
Magle Chemoswed Holding AB
STO:MAGLE
Cash from Operating Activities
kr15.3m
CAGR 3-Years
N/A
CAGR 5-Years
7%
CAGR 10-Years
N/A
No Stocks Found

Genovis AB
Glance View

Market Cap
1.8B SEK
Industry
Life Sciences Tools & Services

Genovis AB engages in the research and development of enzyme products. The company is headquartered in Lund, Skane. The company went IPO on 2005-11-11. The firm offers products within two product portfolios, namely protein portfolio and nano portfolio. The protein portfolio develops products within the areas of cancer, inflammatory and autoimmune diseases. The portfolio comprises FabRICATOR, a genetically modified enzyme the cleaves antibodies in two parts, and IgGZERO, a protein that specifically cleaves the sugar molecules that occur naturally on antibodies. The products within the nano portfolio are primarily directed at the preclinical market. The firm markets and sells its products through dealers and distributors in the European, North American and Asian continents. As of December 31, 2011, it operated a wholly owned subsidiary, Eijdo Research AB.

GENO Intrinsic Value
24.64 SEK
Overvaluation 12%
Intrinsic Value
Price
G

See Also

What is Genovis AB's Cash from Operating Activities?
Cash from Operating Activities
37.3m SEK

Based on the financial report for Jun 30, 2024, Genovis AB's Cash from Operating Activities amounts to 37.3m SEK.

What is Genovis AB's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 5Y
60%

Over the last year, the Cash from Operating Activities growth was -24%. The average annual Cash from Operating Activities growth rates for Genovis AB have been 73% over the past three years , 60% over the past five years .

Back to Top